Onconetix (ONCO) Receivables (2023 - 2026)
Onconetix (ONCO) posted quarterly Receivables of -$6275.0 for Q1 2026, down 122.94% year-over-year from $27350.0 in Q1 2025, and down 102.02% quarter-over-quarter from $310047.0 in Q4 2025.
Onconetix (ONCO) Receivables (2023 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Receivables for 4 consecutive years, with -$6275.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables fell 122.94% year-over-year to -$6275.0; the TTM figure through Mar 2026 stood at -$6275.0 (down 122.94% YoY), while the FY2025 annual figure was $600000.0, up 735.25% from the prior year.
- Receivables retreated to -$6275.0 in Q1 2026 per ONCO's latest filing, from $310047.0 in the prior quarter.
- Across five years, Receivables topped out at $534313.0 in Q2 2024 and bottomed at -$6275.0 in Q1 2026.
- Historically, Receivables has averaged $177064.6 across 4 years, with a median of $49592.5 in 2024.
- Annual changes were most pronounced in 2025 — Receivables jumped 331.61% — and 2026, when it slumped 122.94%.
- Onconetix's Receivables stood at $308731.0 in 2023, then tumbled by 76.73% to $71835.0 in 2024, then surged by 331.61% to $310047.0 in 2025, then tumbled by 102.02% to -$6275.0 in 2026.
- Business Quant data shows ONCO's Receivables at -$6275.0 in Q1 2026, $310047.0 in Q4 2025, and $13046.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | 8,523.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8,523.00 |
| Mar 31, 2026 | -6,275.00 |
| Dec 31, 2025 | 310,047.00 |
| Sep 30, 2025 | 13,046.00 |
| Jun 30, 2025 | 24,599.00 |
| Mar 31, 2025 | 27,350.00 |
| Dec 31, 2024 | 71,835.00 |
| Sep 30, 2024 | 461,000.00 |
| Jun 30, 2024 | 534,313.00 |
| Mar 31, 2024 | 26,000.00 |
| Dec 31, 2023 | 308,731.00 |